These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26137087)

  • 21. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
    Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
    Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secretion of transforming growth factor-beta 1 and -beta 2 by malignant glioma cells.
    Sasaki A; Naganuma H; Satoh E; Nagasaka M; Isoe S; Nakano S; Nukui H
    Neurol Med Chir (Tokyo); 1995 Jul; 35(7):423-30. PubMed ID: 7477684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma.
    Wick W; Naumann U; Weller M
    Curr Pharm Des; 2006; 12(3):341-9. PubMed ID: 16454748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.
    Levin VA; Lamborn K; Wara W; Davis R; Edwards M; Rabbitt J; Malec M; Prados MD
    Neuro Oncol; 2000 Jan; 2(1):22-8. PubMed ID: 11302250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma.
    Yamada N; Kato M; Yamashita H; Nistér M; Miyazono K; Heldin CH; Funa K
    Int J Cancer; 1995 Aug; 62(4):386-92. PubMed ID: 7635563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
    Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
    Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lomustine and Bevacizumab in Progressive Glioblastoma.
    Wick W; Gorlia T; Bendszus M; Taphoorn M; Sahm F; Harting I; Brandes AA; Taal W; Domont J; Idbaih A; Campone M; Clement PM; Stupp R; Fabbro M; Le Rhun E; Dubois F; Weller M; von Deimling A; Golfinopoulos V; Bromberg JC; Platten M; Klein M; van den Bent MJ
    N Engl J Med; 2017 Nov; 377(20):1954-1963. PubMed ID: 29141164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
    Yagiz K; Huang TT; Lopez Espinoza F; Mendoza D; Ibañez CE; Gruber HE; Jolly DJ; Robbins JM
    Neuro Oncol; 2016 Oct; 18(10):1390-401. PubMed ID: 27166379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.
    Galldiks N; Dunkl V; Ceccon G; Tscherpel C; Stoffels G; Law I; Henriksen OM; Muhic A; Poulsen HS; Steger J; Bauer EK; Lohmann P; Schmidt M; Shah NJ; Fink GR; Langen KJ
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2377-2386. PubMed ID: 29982845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells.
    Gramatzki D; Pantazis G; Schittenhelm J; Tabatabai G; Köhle C; Wick W; Schwarz M; Weller M; Tritschler I
    Oncogene; 2009 Jul; 28(28):2593-605. PubMed ID: 19465936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
    Beije N; Kraan J; Taal W; van der Holt B; Oosterkamp HM; Walenkamp AM; Beerepoot L; Hanse M; van Linde ME; Otten A; Vernhout RM; de Vos FY; Gratama JW; Sleijfer S; van den Bent MJ
    Br J Cancer; 2015 Jul; 113(2):226-31. PubMed ID: 26042933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of tamoxifen on the secretion of transforming growth factor-beta2 (TGF-beta2) in glioblastomas: in vitro and in vivo findings.
    Puchner MJ; Köppen JA; Zapf S; Knabbe C; Westphal M
    Anticancer Res; 2002; 22(1A):45-51. PubMed ID: 12017331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma.
    Giannelli G; Villa E; Lahn M
    Cancer Res; 2014 Apr; 74(7):1890-4. PubMed ID: 24638984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.
    Tran TT; Uhl M; Ma JY; Janssen L; Sriram V; Aulwurm S; Kerr I; Lam A; Webb HK; Kapoun AM; Kizer DE; McEnroe G; Hart B; Axon J; Murphy A; Chakravarty S; Dugar S; Protter AA; Higgins LS; Wick W; Weller M; Wong DH
    Neuro Oncol; 2007 Jul; 9(3):259-70. PubMed ID: 17522330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.
    Papa E; Weller M; Weiss T; Ventura E; Burghardt I; Szabó E
    Cell Death Dis; 2017 Dec; 8(12):3210. PubMed ID: 29238047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor.
    Wesolowska A; Kwiatkowska A; Slomnicki L; Dembinski M; Master A; Sliwa M; Franciszkiewicz K; Chouaib S; Kaminska B
    Oncogene; 2008 Feb; 27(7):918-30. PubMed ID: 17684491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of endothelin-1 and transforming growth factor beta 1 with malignancy and vascularity in human gliomas.
    Stiles JD; Ostrow PT; Balos LL; Greenberg SJ; Plunkett R; Grand W; Heffner RR
    J Neuropathol Exp Neurol; 1997 Apr; 56(4):435-9. PubMed ID: 9100674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Norepinephrine induced epithelial-mesenchymal transition in HT-29 and A549 cells in vitro.
    Zhang J; Deng YT; Liu J; Wang YQ; Yi TW; Huang BY; He SS; Zheng B; Jiang Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):423-35. PubMed ID: 26358081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma.
    Kawataki T; Naganuma H; Sasaki A; Yoshikawa H; Tasaka K; Nukui H
    Neuropathology; 2000 Sep; 20(3):161-9. PubMed ID: 11132930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role for transforming growth factor-beta (TGF-beta) in human cancer.
    Gold LI
    Crit Rev Oncog; 1999; 10(4):303-60. PubMed ID: 10654929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.